EGLN2: Prolyl hydroxylase EGLN2
Prolyl hydroxylase that mediates hydroxylation of proline residues in target proteins, such as ATF4, IKBKB, CEP192 and HIF1A.
- Drugs that act on it: 2
- Approved: 1
- In phases 1 to 3: 1
- Sponsors: 2
Who is on it, and how far along
Every drug ChEMBL records acting on EGLN2, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule 2
The landscape
Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.| VadadustatBoxed warning | Approved | Akebia Therapeutics | Small molecule | InhibitorHypoxia-inducible factor prolyl hydroxylase 1 inhibitor | 3 |
| Molidustat | Phase 2 | Bayer | Small molecule | InhibitorHypoxia-inducible factor prolyl hydroxylase 1 inhibitor | 1 |
Open trials
The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 4 in all, from ClinicalTrials.gov.| Safety and Efficacy of a Phased Transition From Epogen to Three Times Weekly Oral Vadadustat for the Treatment of Anemia in Subjects Receiving In-Center Hemodialysis | Vadadustat | Phase 3 | Not yet recruiting | Geoff Block | May 4, 2026 |
| Effects of Vadadustat on Anemia, Quality of Life, and Inflammation in Dialysis Patients | Vadadustat | Phase 4 | Not yet recruiting | Mackay Memorial Hospital | Apr 17, 2026 |
| Vadadustat for the Treatment of Nonintubated Acute Respiratory Distress Syndrome Due to Pathogen-Associated Lung Injury | Vadadustat | Phase 2 / Phase 3 | Recruiting | Paul Potnuru | Jul 25, 2025 |
| A Study to Learn More About the Long-term Safety and Effectiveness of Molidustat as a Treatment for Japanese Men and Women With Renal Anemia | Molidustat | — | Active, not recruiting | Bayer | May 24, 2021 |
Diseases most associated with it
Open Targets association score, 0 to 1; all associations- Anemia
- 0.60
- Chronic renal failure syndrome
- 0.37
- Stage 5 chronic kidney disease
- 0.33
- Neurodegenerative disease
- 0.28
- Familial colorectal cancer
- 0.27
- Kidney disorder
- 0.26
- Smoking behavior
- 0.18
- Osteoarthritis
- 0.18
Genes and related targets
Complexes and families that share a gene with this target- Genes
- EGLN2
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3028, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt Q96KS0, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets